BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 26315556)

  • 1. Myricetin inhibits proliferation of cisplatin-resistant cancer cells through a p53-dependent apoptotic pathway.
    Huang H; Chen AY; Ye X; Li B; Rojanasakul Y; Rankin GO; Chen YC
    Int J Oncol; 2015 Oct; 47(4):1494-502. PubMed ID: 26315556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chaetoglobosin K induces apoptosis and G2 cell cycle arrest through p53-dependent pathway in cisplatin-resistant ovarian cancer cells.
    Li B; Gao Y; Rankin GO; Rojanasakul Y; Cutler SJ; Tu Y; Chen YC
    Cancer Lett; 2015 Jan; 356(2 Pt B):418-33. PubMed ID: 25304379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
    Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
    Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.
    Ma JJ; Chen BL; Xin XY
    Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Theaflavin-3, 3'-digallate induces apoptosis and G2 cell cycle arrest through the Akt/MDM2/p53 pathway in cisplatin-resistant ovarian cancer A2780/CP70 cells.
    Tu Y; Kim E; Gao Y; Rankin GO; Li B; Chen YC
    Int J Oncol; 2016 Jun; 48(6):2657-65. PubMed ID: 27082635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory effect of black tea pigments, theaflavin‑3/3'-gallate against cisplatin-resistant ovarian cancer cells by inducing apoptosis and G1 cell cycle arrest.
    Pan H; Wang F; Rankin GO; Rojanasakul Y; Tu Y; Chen YC
    Int J Oncol; 2017 Nov; 51(5):1508-1520. PubMed ID: 29048667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Purified Tea (
    Ren N; Chen L; Li B; Rankin GO; Chen YC; Tu Y
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galangin, a Flavonoid from Lesser Galangal, Induced Apoptosis via p53-Dependent Pathway in Ovarian Cancer Cells.
    Huang H; Chen AY; Ye X; Guan R; Rankin GO; Chen YC
    Molecules; 2020 Mar; 25(7):. PubMed ID: 32235536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Knockdown of eIF4E suppresses cell proliferation, invasion and enhances cisplatin cytotoxicity in human ovarian cancer cells.
    Wan J; Shi F; Xu Z; Zhao M
    Int J Oncol; 2015 Dec; 47(6):2217-25. PubMed ID: 26498997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
    Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.
    Fraser M; Bai T; Tsang BK
    Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Relationship between the Akt-regulated direct p53 mitochondrial translocation and the resistance to cisplatin of ovarian cancer cells].
    Zhou Y; Wang SY; Yang XK; Wang HM
    Zhonghua Zhong Liu Za Zhi; 2011 Feb; 33(2):97-100. PubMed ID: 21575475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
    Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
    Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy.
    He J; Yu JJ; Xu Q; Wang L; Zheng JZ; Liu LZ; Jiang BH
    Autophagy; 2015; 11(2):373-84. PubMed ID: 25650716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
    Kozubík A; Horváth V; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Zák F; Mistr A; Turánek J
    Biochem Pharmacol; 2005 Feb; 69(3):373-83. PubMed ID: 15652229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53.
    Jones NA; Turner J; McIlwrath AJ; Brown R; Dive C
    Mol Pharmacol; 1998 May; 53(5):819-26. PubMed ID: 9584207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines.
    Henkels KM; Turchi JJ
    Cancer Res; 1999 Jul; 59(13):3077-83. PubMed ID: 10397248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1/Ref-1 inhibitor.
    Zhang Y; Wang J; Xiang D; Wang D; Xin X
    Int J Oncol; 2009 Nov; 35(5):1069-79. PubMed ID: 19787261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin.
    Kolfschoten GM; Hulscher TM; Schrier SM; van Houten VM; Pinedo HM; Boven E
    Gynecol Oncol; 2002 Mar; 84(3):404-12. PubMed ID: 11855878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apoptosis as a measure of chemosensitivity to cisplatin and taxol therapy in ovarian cancer cell lines.
    Gibb RK; Taylor DD; Wan T; O'Connor DM; Doering DL; Gerçel-Taylor C
    Gynecol Oncol; 1997 Apr; 65(1):13-22. PubMed ID: 9103385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.